Program
vadadustat
Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.
Drug pageVadadustat: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akebia Therapeuticsits history only | 320 open or running | phase 3since Jan 4, 2016 | Nov 5, 2010 | none ahead |
| Tanabe Pharmaits history only | 40 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
Also a collaborator on its studies: Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 17 earlier studies, Nov 5, 2010 to Oct 30, 2017.
- Dec 9, 2015Named vadadustatINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AKB-6548, MT-6548
- Dec 27, 2017Phase 3 study in AnemiaTanabe Pharma · NCT03402386 · 42 enrolled · Japan
- Feb 14, 2018Phase 3 study in AnemiaTanabe Pharma · NCT03439137 · 323 enrolled · Japan
- Mar 5, 2018Phase 3 study in AnemiaTanabe Pharma · NCT03461146 · 24 enrolled · Japan
- Jun 12, 2018Phase 1 study in HealthyAkebia Therapeutics · NCT03639155 · 50 enrolled · United States
- Aug 31, 2018Phase 1 study in HealthyAkebia Therapeutics · NCT03657290 · 54 enrolled · United States
- Dec 3, 2018Phase 2 study in AnemiaAkebia Therapeutics · NCT03799627 · 175 enrolled · United States
- Dec 27, 20185 phase 1 studiesAkebia Therapeutics · NCT03801759, NCT03801746, NCT03801733 and 2 more
- Jun 18, 2019Phase 1 study in AnemiaAkebia Therapeutics · NCT03992066 · 46 enrolled · United States
- Mar 5, 2020Phase 1 study in Healthy VolunteersAkebia Therapeutics · NCT04299633 · 54 enrolled · Canada
- Mar 16, 2020Phase 3 study in AnemiaAkebia Therapeutics · NCT04313153 · 319 enrolled · United States, Czechia, Hungary and more
- Nov 2, 2020Phase 2 study in Renal Insufficiency, ChronicAkebia Therapeutics · NCT04707573 · 22 enrolled · United States
- Jan 12, 2021Phase 3 study in AnemiaAkebia Therapeutics · NCT04707768 · 456 enrolled · United States
- Sep 28, 20212 phase 3 studies in AnemiaAkebia Therapeutics · NCT05082584, NCT05082571
- Mar 27, 2025Phase 3 study in Renal Insufficiency, ChronicAkebia Therapeutics · NCT06901505 · 353 enrolled · United States
TargetBeta
“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06901505Renal Insufficiency, Chronic · United States | 3 | Completed | Akebia Therapeutics | Aug 12, 2026 | 353 |
| NCT05082584Anemia · United States | 3 | Withdrawn | Akebia Therapeutics | Jul 2026 | 0 |
| NCT05082571Anemia · United States | 3 | Withdrawn | Akebia Therapeutics | Jul 2026 | 0 |
| NCT04707768Anemia · United States | 3 | Completed | Akebia Therapeutics | Jan 6, 2023 | 456 |
| NCT04707573Renal Insufficiency, Chronic · United States | 2 | Completed | Akebia Therapeutics | Sep 24, 2010 | 22 |
| NCT04313153Anemia · United States, Czechia, Hungary and more | 3 | Completed | Akebia Therapeutics | Nov 26, 2021 | 319 |
| NCT04299633Healthy Volunteers · Canada | 1 | Completed | Akebia Therapeutics | Aug 2, 2020 | 54 |
| NCT03992066Anemia · United States | 1 | Completed | Akebia Therapeutics | May 5, 2020 | 46 |
| NCT03801759Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Sep 30, 2018 | 62 |
| NCT03801746Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Aug 15, 2018 | 40 |
| NCT03801733Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Nov 24, 2018 | 134 |
| NCT03799848Hepatic Impairment · United States | 1 | Completed | Akebia Therapeutics | Oct 18, 2018 | 24 |
| NCT03789032Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Nov 9, 2018 | 20 |
| NCT03799627Anemia · United States | 2 | Completed | Akebia Therapeutics | Jun 5, 2020 | 175 |
| NCT03657290Healthy · United States | 1 | Completed | Akebia Therapeutics | Oct 16, 2018 | 54 |
| NCT03639155Healthy · United States | 1 | Completed | Akebia Therapeutics | May 23, 2018 | 50 |
| NCT03461146Anemia · Japan | 3 | Completed | Tanabe Pharma | Dec 3, 2018 | 24 |
| NCT03439137Anemia · Japan | 3 | Completed | Tanabe Pharma | Dec 12, 2018 | 323 |
| NCT03402386Anemia · Japan | 3 | Completed | Tanabe Pharma | Nov 22, 2018 | 42 |
| NCT03329196Anemia · Japan | 3 | Completed | Tanabe Pharma | Jan 8, 2019 | 304 |
| NCT03242967Anemia · United States | 3 | Withdrawn | Akebia Therapeutics | Feb 12, 2018 | 0 |
| NCT03140722Anemia · United States | 2 | Terminated | Akebia Therapeutics | Mar 21, 2018 | 2 |
| NCT03054350Anemia · Japan | 2 | Completed | Akebia Therapeutics | Oct 24, 2017 | 60 |
| NCT03054337Anemia · Japan | 2 | Completed | Akebia Therapeutics | Jul 4, 2017 | 51 |
| NCT02892149Anemia · United States, Argentina, Australia and more | 3 | Completed | Akebia Therapeutics | Jan 16, 2020 | 3,554 |
| NCT02865850Anemia · United States, Argentina, Brazil and more | 3 | Completed | Akebia Therapeutics | Jan 31, 2020 | 369 |
| NCT02680574Anemia · United States, Argentina, Australia and more | 3 | Completed | Akebia Therapeutics | Jun 18, 2020 | 1,725 |
| NCT02648347Anemia · United States, Argentina, Australia and more | 3 | Completed | Akebia Therapeutics | Jun 4, 2020 | 1,751 |
| NCT02502500Healthy Volunteers | 1 | Completed | Akebia Therapeutics | Jul 2015 | 12 |
| NCT02412449Anemia · United States | 1 | Completed | Akebia Therapeutics | Apr 2015 | 18 |
| NCT02327546Anemia · United States | 1 | Completed | Akebia Therapeutics | Dec 2014 | 10 |
| NCT02260193Anemia · United States | 2 | Completed | Akebia Therapeutics | Jul 22, 2015 | 94 |
| NCT02062203Anemia · United States | 1 | Completed | Akebia Therapeutics | Apr 2014 | 50 |
| NCT01906489Anemia · United States | 2 | Completed | Akebia Therapeutics | Sep 3, 2014 | 210 |
| NCT01381094Anemia · United States | 2 | Completed | Akebia Therapeutics | Feb 16, 2012 | 93 |
| NCT01235936Anemia · United States | 2 | Completed | Akebia Therapeutics | Apr 13, 2011 | 10 |
How it is read
Names in the registry
- “Vadadustat”, 19 entries
- “AKB-6548”, 8 entries
- “MT-6548”, 4 entries
- “vadadustat”, 4 entries
- “vadadustat reference tablets”, 1 entry
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.